Supplement for FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Published: 7 November 2024| Version 1 | DOI: 10.17632/23tcsdt2hc.1
Contributors:
,
,
,
,
,
,
,
,
,
,
,

Description

Supplemental material in support of the article "FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis"

Files

Categories

Dermatology

Funding

Janssen Research and Development

Licence